Brands
Ronojit Biswas to take charge as GSK Pharma CFO
Juby Chandy exits for Apac finance role; shares slip 0.97 per cent
MUMBAI: GlaxoSmithKline Pharmaceuticals Limited on Monday named Ronojit Biswas as whole-time director and chief financial officer for a three-year term starting 1 April, 2026, signalling a steady internal succession at the drugmaker’s India arm.
Biswas will replace Juby Chandy, who steps down as whole-time director and CFO on 11 March, 2026, after being elevated to lead Apac finance within the wider GSK Group.
A company lifer, Biswas joined GSK in India in 1999 as a management trainee and has since built a 25-year career across India, Vietnam, Singapore, Brazil and the UK. Most recently, he served as senior finance director – global product strategy, based in Singapore.
He has previously held CFO roles in Brazil and Vietnam and was regional controller for GSK’s international region, overseeing financial reporting, performance management and internal controls: a portfolio that sharpened his exposure to global compliance and capital discipline.
Biswas holds a postgraduate degree in management (finance) from Management Development Institute, Gurugram, and a bachelor of commerce (honours) from St. Xavier’s College, Kolkata.
Shares of the company were trading at Rs 2,545.00, down Rs 25.00, or 0.97 per cent, at 12:40 pm, reflecting a muted market response to the boardroom reshuffle.
Brands
Dabur buys minority stake in Ras Beauty for Rs 60 crore
Dabur Ventures deal backs fast-growing luxury skincare brand
MUMBAI: Dabur India Limited has dipped into the world of luxury skincare, signing a definitive agreement to acquire a minority stake in Ras Beauty Private Limited for Rs 60 crore. The investment marks the first bet from Dabur Ventures, the FMCG major’s Rs 500 crore platform set up in October 2025 to back high-potential, new-age direct-to-consumer brands.
Founded in Raipur by Shubhika Jain, her sister Suramya Jain and their mother Sangeeta Jain, Ras Beauty has grown from a family-led passion project into a fast-scaling “Farm-to-Face” skincare label. Its range of face elixirs, serums and moisturisers blends essential oils with nature-derived actives, striking a balance between botanical purity and laboratory precision.
The numbers tell their own story. Ras has clocked a three-year Cagr of around 75 per cent and an annual run rate of approximately Rs 100 crore, all while maintaining strong gross margins. That growth has been fuelled by a digital-first approach, in-house R&D and manufacturing, and a sharp focus on clean, sustainable sourcing.
Dabur India executive director and group head corporate strategy Abhinav Dhall, said the company was drawn to Ras’s distinct positioning at the intersection of nature, science and luxury. He added that the premium beauty segment is poised for robust expansion over the coming decade, and that Ras is well placed to capture that opportunity.
For Ras, the partnership is as much about scale as it is about shared philosophy. Co-founder and CEO Shubhika Jain said Dabur’s 141-year legacy of building trusted, purpose-led brands makes it a natural ally. The capital infusion, she noted, will help accelerate the brand’s omnichannel footprint, deepen research capabilities and invest in team and brand building, with an eye on establishing Ras as a leading Indian luxury skincare name both domestically and overseas.
With this move, Dabur is not just investing in a skincare label. It is placing an early wager on India’s growing appetite for premium, conscious beauty, and signalling that heritage FMCG players are ready to play in the new-age D2C arena.
